Anti-IgE antibodies of the IgG class, such as aεFab, directed against the Fc region clearly have potential as anti-allergy therapeutics if, by either steric or allosteric means, they inhibit FcεRI or CD23 engagement. The gene discussed is IGHE; the disease is Allergy.